Posted by admin on May 13th, 2022

Sally Beauty Holdings, Inc. (NYSE:SBH – Get Rating) – Stock analysts at Oppenheimer lowered their Q3 2022 EPS estimates for shares of Sally Beauty in a report issued on Wednesday, May 11th. Oppenheimer analyst R. Parikh now expects that the specialty retailer will post earnings of $0.60 per share for the quarter, down from their prior estimate of $0.66. Oppenheimer currently has a “Market Perform” rating on the stock.

Other research analysts have also issued reports about the company. Cowen lowered their price target on Sally Beauty from $30.00 to $20.00 in a research report on Friday, May 6th. DA Davidson lowered their price target on Sally Beauty from $22.00 to $19.50 in a research report on Friday, February 4th. Zacks Investment Research lowered Sally Beauty from a “hold” rating to a “strong sell” rating and set a $13.00 target price for the company. in a report on Tuesday. Cowen decreased their target price on Sally Beauty from $30.00 to $20.00 in a report on Friday, May 6th. Finally, StockNews.com lowered Sally Beauty from a “buy” rating to a “hold” rating in a report on Monday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $19.58.

SBH opened at $14.77 on Friday. Sally Beauty has a 52 week low of $13.95 and a 52 week high of $23.47. The business has a fifty day simple moving average of $15.97 and a 200-day simple moving average of $17.55. The firm has a market cap of $1.58 billion, a P/E ratio of 6.51 and a beta of 1.34. The company has a quick ratio of 0.59, a current ratio of 2.27 and a debt-to-equity ratio of 5.08.

Sally Beauty (NYSE:SBH – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The specialty retailer reported $0.47 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.04). Sally Beauty had a return on equity of 104.07% and a net margin of 6.66%. The firm had revenue of $911.40 million for the quarter, compared to analysts’ expectations of $951.20 million. During the same quarter in the prior year, the business earned $0.57 earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis.

Hedge funds and other institutional investors have recently made changes to their positions in the business. US Bancorp DE lifted its holdings in Sally Beauty by 43.4% during the 3rd quarter. US Bancorp DE now owns 1,881 shares of the specialty retailer’s stock worth $32,000 after buying an additional 569 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in Sally Beauty by 65.8% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 2,001 shares of the specialty retailer’s stock worth $34,000 after buying an additional 794 shares during the last quarter. Counterpoint Mutual Funds LLC purchased a new stake in Sally Beauty during the 1st quarter worth about $66,000. Huntington National Bank lifted its holdings in Sally Beauty by 39.8% during the 4th quarter. Huntington National Bank now owns 3,768 shares of the specialty retailer’s stock worth $70,000 after buying an additional 1,072 shares during the last quarter. Finally, Nisa Investment Advisors LLC purchased a new stake in Sally Beauty during the 4th quarter worth about $89,000.

Sally Beauty Company Profile (Get Rating)

Sally Beauty Holdings, Inc operates as a specialty retailer and distributor of professional beauty supplies. The company operates through two segments, Sally Beauty Supply and Beauty Systems Group. The Sally Beauty Supply segment offers beauty products, including hair color and care products, skin and nail care products, styling tools, and other beauty products for retail customers, salons, and salon professionals.

Receive News & Ratings for Sally Beauty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sally Beauty and related companies with MarketBeat.com's FREE daily email newsletter.

Q2 2022 Earnings Forecast for Aclaris Therapeutics, Inc. Issued By SVB Leerink (NASDAQ:ACRS)

SQZ Biotechnologies (NYSE:SQZ) to Post Q3 2022 Earnings of ($0.71) Per Share, Zacks Investment Research Forecasts